The Bio Report

Evaluate Pharma, in its latest World Preview report, is projecting solid growth for prescription drug sales through 2022. Driving that growth is both the new products expected to come to market during that time and the industry’s embrace of orphan drugs, the source of half of that growth. We spoke to Antonio Iervolino, head of forecasting for Evaluate, about the new report, the growing number of drug approvals, and the challenges drugmakers face that could alter the outlook for the industry.